HAEMONETICS CORP — Director's Dealing 2012

Oct 26, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2012-10-24

Reporting Person: LINDOP CHRISTOPHER J (CFO & Vice President of)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-10-24	Common Stock	A	2496.0	$0.0	Acquired	15803.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-10-24	Non-Qualified Stock Option (right to buy)	$78.11	A	23249.0	Acquired	2019-10-24	Common Stock (23249.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$52.63	2015-10-23	Common Stock (49020.0)	49020.0	Direct
Non-Qualified Stock Option (right to buy)	$52.94	2016-10-27	Common Stock (22036.0)	22036.0	Direct
Non-Qualified Stock Option (right to buy)	$54.55	2015-10-22	Common Stock (21441.0)	21441.0	Direct
Non-Qualified Stock Option (right to buy)	$54.99	2017-10-27	Common Stock (25095.0)	25095.0	Direct
Non-Qualified Stock Option (right to buy)	$61.34	2018-10-25	Common Stock (24153.0)	24153.0	Direct

Footnotes

F1: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

F4: Grant to reporting person of right to buy shares of common stock vesting in annual increments over a 5 year period beginning on the first anniversary of the date of grant.